Product image of Mibg (I123) Injection Curium Netherlands (Iobenguane Sulfate I-123) supplied by GNH India

Mibg (I123) Injection Curium Netherlands

Active Ingredient:
Iobenguane Sulfate I-123
Origin:
EU

Mibg (I123) Injection Curium Netherlands (Iobenguane Sulfate I-123)

Iobenguane Sulfate I-123, the active ingredient in Mibg (I123) Injection Curium Netherlands, is a radiopharmaceutical presented as an injection for intravenous use. It is employed to visualize sympathetic nervous system activity in patients being evaluated for neuroendocrine tumours and cardiac innervation disorders.

GNH India supplies Mibg (I123) Injection Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and diagnostic imaging clinics worldwide.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mibg (Iobenguane Sulfate I-123) is used in diagnostic imaging of adrenergic tissue disorders.

  • Pheochromocytoma and paraganglioma: enables precise localisation of catecholamine‑producing tumours for surgical planning.
  • Neuroblastoma: highlights tumour sites in paediatric patients to guide treatment decisions.
  • Cardiac sympathetic innervation assessment: evaluates sympathetic nerve function in heart failure or arrhythmia risk stratification.

How It Works

  • Iobenguane Sulfate I-123 is taken up by adrenergic nerve terminals via the norepinephrine transporter (NET). Once inside sympathetic neurons, the radiolabelled analogue is stored in neurosecretory granules, allowing gamma‑camera imaging to map sympathetic activity in tumours or cardiac tissue.

Side Effects

Mibg (Iobenguane Sulfate I-123) may cause a range of adverse reactions following intravenous administration.

Common Side Effects

  • Injection site pain or erythema
  • Nausea or vomiting
  • Headache
  • Transient flushing or warmth
  • Mild hypertension or blood pressure fluctuation
  • Minor allergic skin reaction (rash or pruritus)

Serious or Rare Side Effects

  • Anaphylaxis or severe allergic reaction
  • Significant hypotension or cardiovascular collapse
  • Radiation‑induced skin injury at injection site
  • Thyroid dysfunction due to iodine exposure
  • Severe arrhythmias in patients with underlying cardiac disease
  • Persistent nausea or vomiting requiring medical intervention

Precautions & Warnings

When using Mibg (Iobenguane Sulfate I-123), clinicians should observe several safety measures.

  • Pregnancy: unknown risk; avoid unless essential and discuss with obstetric specialist.
  • Breastfeeding: unknown safety; consider discontinuing nursing during and after administration.
  • Renal impairment: monitor renal function as clearance may be reduced.
  • Thyroid blocking: assess need for iodine prophylaxis to prevent thyroid uptake of free iodine.
  • Radiation safety: ensure staff wear appropriate shielding and follow local radiation protection guidelines.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mibg (Iobenguane Sulfate I-123) can interact with other agents that affect sympathetic activity or iodine metabolism.

Major Interactions (Avoid)

  • Sympathetic agonists (e.g., epinephrine) may alter tracer distribution and compromise image quality.
  • Thyroid blocking agents (e.g., potassium iodide) can reduce radiotracer uptake in target tissues.
  • Concurrent radiopharmaceuticals with overlapping gamma emissions may cause imaging interference.
  • High‑dose catecholamine‑releasing drugs can produce false‑negative results.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt tracer uptake in cardiac studies; monitor imaging outcomes.
  • Calcium channel blockers: possible effect on vascular tone influencing distribution.
  • Diuretics: altered renal clearance may affect background activity.
  • Certain antidepressants (e.g., MAO inhibitors): may modify norepinephrine transporter activity.

Frequently Asked Questions

Mibg (I123) Injection, containing Iobenguane Sulfate I-123, is a diagnostic radiopharmaceutical used to image adrenergic tissues. It helps locate pheochromocytoma and paraganglioma tumours, detect neuroblastoma lesions, and assess cardiac sympathetic innervation in heart disease.

Iobenguane Sulfate I-123 mimics norepinephrine and is taken up by the norepinephrine transporter into sympathetic nerve endings. The I‑123 radioisotope emits gamma photons that are captured by a gamma camera, producing images of sympathetic activity in the body.

The administered activity of Mibg (I123) Injection is determined by the prescribing physician based on the specific diagnostic indication, patient weight, and imaging protocol. Exact dosing is individualized and should follow local regulatory and institutional guidelines.

The safety of Iobenguane Sulfate I-123 in pregnancy and lactation has not been established. It should be used only if the potential diagnostic benefit outweighs the theoretical risk, and alternative imaging methods should be considered when possible.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mibg (Iobenguane Sulfate I-123) is specifically taken up by adrenergic tissue, making it ideal for catecholamine‑producing tumours such as pheochromocytoma. Other agents like 18F‑FDG PET target glucose metabolism and are less selective for adrenergic tumours, so Mibg provides higher specificity for these indications.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. Use aseptic technique for preparation, and follow local radiation safety regulations during handling and administration.

Mibg (I123) Injection is administered intravenously by a qualified healthcare professional. After injection, a waiting period (typically 15‑24 hours) allows the tracer to accumulate in target tissues before gamma‑camera imaging is performed.

Serious risks include severe allergic reactions (anaphylaxis), significant blood pressure changes, radiation‑induced skin injury at the injection site, and rare thyroid dysfunction due to iodine exposure. Immediate medical attention is required if any severe reaction occurs.

Patients with known hypersensitivity to Iobenguane Sulfate I-123 or any component of the formulation should avoid the product. It is also contraindicated in individuals where radiation exposure poses an unacceptable risk, such as certain pregnant patients, unless the diagnostic benefit clearly outweighs the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Iobenguane Sulfate I-123

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT